{"id":"W3088769124","doi":"10.1016/j.annonc.2020.08.2271","title":"LBA41 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":73,"is_retracted":false,"has_abstract":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Oncology; Phases of clinical research; Lenvatinib; Clinical trial; Cancer; Gastroenterology; Sorafenib; Immunotherapy; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001047994,0.001137491,0.001405032,0.0004627806,0.0003506017,0.001416184,0.000832309,0.001083582,0.005429912],"category_scores_gemma":[0.0005020205,0.0005744502,0.001375915,0.0004594776,0.0007304309,0.0008523253,0.0004582546,0.004182884,0.001398138],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001060916,"about_ca_system_score_gemma":0.001467883,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001438688,"about_ca_topic_score_gemma":0.004413787,"domain_scores_codex":[0.9997118,0.000115546,0.00001209385,0.00004843463,0.00002805848,0.00008418095],"domain_scores_gemma":[0.9996884,0.00003806908,0.00004080844,0.00001798866,0.00001375235,0.0002010824],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.559944,0.06387996,0.01024776,0.001797166,0.003634213,0.0004524468,0.0004427419,0.005875248,0.06268134,0.001065848,0.01350996,0.2764694],"study_design_scores_gemma":[0.5208902,0.4292806,0.02536086,0.0001067282,0.001250783,0.0006632057,0.0001659441,0.003055957,0.005396977,0.0004950828,0.01326201,0.00007167836],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9857189,0.004572162,0.0004500028,0.001025746,0.0002713091,0.001250308,0.001722464,0.0001919635,0.004797133],"genre_scores_gemma":[0.9809226,0.003723483,0.001314804,0.001396808,0.0001973273,0.001366928,0.004080163,0.00004120818,0.00695682],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005429912,"threshold_uncertainty_score":0.01816493,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0351059942400495,"score_gpt":0.3413605588032494,"score_spread":0.3062545645631999,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}